HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France Reverse-Switches Flurbiprofen Against Backdrop Of NSAID Concerns

Executive Summary

France has unexpectedly reverse switched to prescription status flurbiprofen, the active ingredient in Reckitt's Strefen. The move comes shortly after the country's medicines agency warned of serious adverse events related to certain NSAIDs.

You may also be interested in...



EU Warns Flurbiprofen Can Potentially Mask Infection Symptoms

Popular OTC sore throat treatment flurbiprofen can possibly mask the symptoms of infection and lead to treatment delays, according to EU medicines regulators. Products sold in the EU containing flurbiprofen will soon be required to carry information warning patients and healthcare professionals about this risk. 

Sore Throat Drugs Heading Behind The Counter In France Over Safety Fears

France's drugs agency wants to restrict sales of OTC sore throat treatments marketed by Sanofi and others to behind the pharmacy counter due to fears of potential adverse events.

France's ANSM Moves Paracetamol, Ibuprofen And Aspirin Behind The Counter

France restricts sales of medicines containing paracetamol, ibuprofen and aspirin to behind the pharmacy counter due to safety concerns.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel